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We report here on the cloning of a human intronless gene encoding a member of the G-protein linked somatostatin (SST) receptor subfamily, termed 
SSTR3. Based on the deduced amino acid sequence, this gene encodes a 418 amino acid protein displaying sequence similarity, particularly within 
putative transmembrane domains, with the recently cloned human SSTRl (62%), SSTR2 (64%) and SSTM (58%) receptors. Membranes prepared 
from COS-7 cells transiently expressing the human SSTR3 gene bound [‘251]Leus,o-TrpZZ,Tyr25 SST-28 in a saturable manner with high affiity 
(- 200 PM) and with rank order of potency (D-Ttp* SST-14 > SST-14 > SMS-201-995 > SST-28) indicative of a somatostatin-14 selective receptor. 
The pharmacological profile of the expressed human SSTR3 receptor is similar but not identical to that reported for the rat homolog [(1992) J.
Biol. Chem. 267,20422] where the peptide selectivity is SST-28 t SST-14 X+ SMS-201-995. Northern blot analysis reveals the presence of an SSTR3 
mRNA species of - 5 kb in various regions of the monkey brain, including the frontal cortex, cerebellum, medulla, amygdala, with little or no 
SSTR3 mRNA detectable in brain regions such as the striatum, hippocampus, and olfactory tubercle. The SSTR3 receptor gene maps to human 
chromosome 22. The existence of at least four distinct human genes encoding somatostatin-14 selective receptors with diverse pharmacological 
specificities may help to account for some of the multiple biological actions of somatostatin under normal and pathological conditions. 
Polymerase chain reaction; Neuropeptide; SST-14; SST-28 
1. INTRODUCTION 
Somatostatin (somatotropin release-inhibiting factor 
or SRIF), a tetradecapeptide derived from presomato- 
statin, is a multifunctional peptide located in both the 
central nervous system and peripheral tissue [l-3]. Orig- 
inally isolated from the hypothalamus [l], it has been 
identified in most brain regions as well as such organs 
as the pituitary, pancreas, adrenals, gastrointestinal sys- 
tem and thyroid. Functionally, somatostatin regulates 
the secretion of various hormones and secretory sub- 
stances, including growth hormone, gastrin, glucagon 
and insulin. However, it can also act as a neuromodula- 
tor in the CNS, modulating neuronal activity by facili- 
tating the release of several neurotransmitters including 
dopamine and serotonin [4]. Two forms of somatostatin 
exist, SST-14 and SST-28, and are believed to mediate 
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somatostatin’s functions in a tissue-specific manner. It 
has been postulated that a malfunction in somatostatin 
metabolism contributes to the maintenance of several 
disorders including Alzheimer’s and Parkinson’s de- 
mentia [5,6]. 
Somatostatin is believed to mediate its effects via spe- 
cific cell surface receptors which are coupled to GTP- 
binding proteins (see [3] and [4] for reviews). Pharma- 
cological studies have demonstrated the presence of at 
least two distinct receptor subtypes which possess high 
afhnity, saturable binding sites selective for the two 
native and biologically active forms of somatostatin. 
These findings suggest hat the two peptides, SST-14 
and SST-28, may therefore have different functions, me- 
diated by different receptors and that these receptors 
are expressed in a tissue-specific manner. Somatostatin 
receptors have been observed in many tissues including 
brain, pituitary, pancreas, adrenals and various ‘cell 
lines such as GH3, GH4Cl and AtT-20 pituitary tu- 
mour cells. 
Recent photoaffinity labeling and purification studies 
have also provided evidence for the existence of multiple 
somatostin receptors in the CNS and periphery. These 
reports have postulated a diverse population of recep- 
tors ranging in polypeptide size from 27 to 200 kDa 
[7,8]. It is unclear however, whether this observed diver- 
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sity is due to receptor heterogeneity or experimental 
variability. Ambiguity therefore still remains in the 
number and structure of the somatostatin receptor fam- 
ily which has only begun to be elucidated by the cloning 
of its receptor subtypes [9]. 
Using a strategy based on low stringency screening 
for genes encoding members of the superfamily of re- 
ceptors which couple to G-protein binding [lo], we re- 
port here the isolation of a third human intronless so- 
matostatin receptor gene (SSTR3) located on chromo- 
some 22. The gene encodes for a protein which shares 
considerable amino acid homology to the recently 
cloned human somatostatin receptors SSTRl, SSTR2 
[l l] and SSTR4 [12]. The expressed receptor when 
transfected in COS-7 cells displays a pharmacological 
profile consistent with previously observed somato- 
statin binding sites selective for the SS-14 peptide in 
native membranes, but not with the recently cloned rat 
homolog [13,14] of human SSTR3. 
2. MATERIALS AND METHODS 
2.1. Peptides 
Synthetic SST-14 was obtained from Ayerst Laboratories, Mon- 
treal. SST-28 [D-Trp*]SST-14 and [Leu*,o-Trpz2,Tyti5]SST-28 (LTT 
SS-28) were from Bachem (Marina Del Ray, CA). The octapeptide 
somatostatin analog SMS-201-995 was a gift of Sandoz Pharmaceuti- 
cals (Basel, Switzerland). 
2.2. Cloning of the SSTR3 receptor gene 
A fragment encoding transmembrane domains one to five of the 
human dopamine D5 receptor [151 was radiolabelled with [a-“P]dCTP 
by nick translation (Amersham) and used to probe a human genomic 
ilEMBL3 library. Nylon filters (Colony/Plaque Screen, DuPont) were 
hybridized under low stringency conditions [15] at 42°C for 24 h with 
[a-“PJdCTP (NEN) labeled fragment. Filters were washed twice at 
50°C for 1 h in a 2 x standard saline citrate (SSC/l% SDS solution). 
Hybridizing colonies were selected and sequenced with the dideoxynu- 
cleotide chain termination method using Sequenase version 2.0 (US 
Biochemical) and 7-deaza-GTP. 
From this screening, positive colonies were systematically isolated 
and analyzed by restriction endonuclease and Southern blot analysis. 
A 5.5 kb BumHI fragment (JCI) was isolated, subcloned into pSP73 
and characterised by sequence analysis. 
2.3. Expression and radioligand binding analysis 
The mammalian expression vector containing the SSTR3 receptor 
was constructed by inserting a 2.1 kb NcoUHindIII fragment of the 
human genomic clone JCI into the expression vector pCD-ps., 
Radioligand binding studies were carried out on membranes pre- 
pared from JCI-pCD-ps transfected COS-7 cells using methods previ- 
ously described [12,15]. Cells were harvested, washed with Ca2’/Mg2’- 
free PBS and homogenized in ice-cold 10 mM Tris-HCl (pH 7.4) 
containing 2.5 mM dithiothreitol after removal of nuclear debris. 
Plasma membrane fractions were obtained by centrifugation of the 
homogenate at 20,000 x g for 20 min. The pellets were then washed 
twice with 10 mM Tris-HCl, resuspended and stored at -80°C. 
[‘251]LTT STT-28 was radioiodinated by modification of the chloram- 
ine-T method and purified by reverse phase HPLC on a PBondapak 
C-l 8 column to a specific activity of approximately 1,050 Ciimmol(1 
Ci = 37 GBq) [16]. 
Binding studies were carried out with [“‘I]LTT SST-28 in 50 mM 
HEPES-KOH buffer (pH 7.5) containing 5 mM Mg’+, 0.02% BSA, 
200 kalliketin inhibitor units of Aprotinimml and 0.02 @ml each of 
280 
phenylmethyl-sulfonylfluoride and bacitracin, incubated with 20-40 
pug membrane protein for 30 min at 30°C. Incubations were terminated 
by adding 1 ml of ice-cold HEPES-KOH containing 0.2% BSA, rapid 
centrifugation and washing. Radioactivity associated with membrane 
pellets was quantitated in an LKB gamma spectrometer. Specific bind- 
ing was defined as the difference between total binding and binding 
in the presence of 100 nM SST-14. 
Saturation experiments were performed under equilibrium condi- 
tions with increasing concentrations of [‘251]LTT SST-28 (2.5-1,000 
PM). Competition analyses were carried out by incubating membranes 
with [“‘I]LTT SST-28 (- 60 PM) and increasing concentrations of 
SST peptides. Estimated B,,,, and K, values were obtained using the 
computer program LIGAND as previously described [151. 
2.4. Northern blot analysis 
Poly(A)+ RNA was isolated from several monkey brain regions by 
the guanidium-isothiocyanate method as previously described [lo]. 
Samples were denatured in glyoxal and dimethyl sulfoxide, electro- 
phoresed in a 1% agarose gel and transferred to nylon membrane 
(Hybond, Amersham). The blots were probed with an [a-‘*P]dCTP 
labelled 2.1 kb NcoYHindIII fragment encoding the SSTR3 receptor 
and hybridized under high stringency conditions. The blots were then 
washed twice for 10 mm in 2 x SSC/l 8 SDS at 20°C and twice for 15 
min at 0.5 x SSC/l% SDS at 5O’C. The blots were exposed at -75°C 
to XAR5 film (Kodak). 
2.5. Chromosomal location of the SSTR3 receptor gene 
Amplification of a 410 bp region flanking both the 5’ translated and 
untranslated nucleotides of the human SSTR3 gene was performed to 
determine its chromosomal location. Oligonucleotide primers 5’- 
CAGCACAGAGAAGCCATTCTCTGCTGT-3’ and S-TAGGAC- 
AGGGCGTTCTGG3’ (encompassing nucleotides -72 and 340 
within the 5’ translated and untranslated regions) and target DNA 
(250 ng) from panels of hybrid human-hamster somatic cell lines 
(Bios, New Haven, CT) were submitted to 20 cycles of PCR containing 
2.5 units of Tuq polymerase (Cetus) under the following conditions: 
denature, 1 min at 94°C; annealing, 6O’C 1.5 mitt; primer extension, 
72’C 1.5 min. Aliquots (2 ~1) were then resubmitted to an additional 
20 cycles of PCR under the same conditions. Samples of amplified 
DNA were electrophoresed ina 1.2% agarose gel, transferred to nylon 
(Zeta-probe, Bio-Rad) and hybridized with a [y-“P]ATP labelled 
oligonucleotide probe (5’-GTTCTGATCCCCCTGGTCTAC-3’) lo- 
cated internally (nucleotide 133) to the amplified regions of SSTR3 
under high stringency conditions. The blots were washed twice with 
2 x SSC/l% SDS at 20°C for 10 min, once in 1 x SSC/l% SDS at 5O’C 
for 10 min and exposed to autoradiography for 1 h to XAR-5 film. 
3. RESULTS AND DISCUSSION 
Low stringency screening of human genomic DNA 
with conserved segments of transmembrane one to five 
of the dopamine receptor gene family, generated many 
clones as previously described [lo]. A 5.5 kb BamHI 
fragment (JCI) was isolated, which upon nucleotide se- 
quencing, showed considerable deduced amino acid ho- 
mology to the G-protein coupled peptide receptor fam- 
ily, and more specifically, to recently cloned members 
of the somatostatin receptor family [11,12]. 
Nucleotide sequence analysis of JCI revealed consen- 
sus sequences for a putative initiating methionine [17] 
followed by an open reading frame of 1,254 nucleotides 
encoding a 418 amino acid protein with an estimated 
molecular mass of 45,817. Fig. la and lb depict the 
restriction map, nucleotide and deduced amino acid se- 
quence of the genomic clone, termed SSTR3, respec- 
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5'-TAGCEACTGCTAGCC ATG GAC ATG CTT CAT CCA TCA TCG GTG TCC ACG ACC TCA GAA CCT 
Met Asp Met Le" His Pro Ser Ser Val Ser Thr Thr Ser Gl" Pro 
46 105 
GAG AAT GCC TCC TCG GCC TGG CCC CCA GAT GCC ACC CTG GGC AAC GTG TCG GCG GGC CCA 
Gl" Am Ala Ser Ser Ala Trp Pro Pro Asp Ala Thr Le" Gly Ar Val Ser Ala Gly Pro 
106 A 165 
AGC CCG GCA GGG CTG GCC GTC AGT GGC GTT CTG ATC CCC Cl'2 GTC TAC CTG GTG GTG TGC 
Ser Pro Ala Gly Le" Ala Val Ser Gly Val Leu Ile Pro Leu Val Tyr Leu Val Val Q's 
166 225 
GTG GTG GGC CTG CTG GGT AAC TCG CTG GTC ATC TAT GTG GTC CTG CGG CAC ACG GCC AGC 
Val Val Gly Leu Leu Gly Am Ser Le" Val Ile Tyr Val Val Le" Arg His Thr Ala Ser 
226 285 
CCT TCA GTC ACC AAC GTC TAC ATC CTC AAC CTG GCG CTG GCC GAC GAG CTC TTC An: CTG 
Pro Ser Val Thr Asn Val Tyr Ile Leu Asn Leu Ala Le" Ala Asp Gl" Le" Phe Met Le" 
286 345 
GGG CTG CCC TTC CTG GCC GCC CAG AAC GCC CTG TCC TAC TGG CCC TTC GGC TCC CTC ATG 
Gly Le" Pro Phe Le" Ala Ala Gln Asn Ala Le" Ser Tyr Trp Pro Phe Gly Ser Le" Met 
346 405 
TGC CGC CTG GTC ATG GCG GTG GAT GGC ATC AAC CAG TTC ACC AGC ATA TTC TGC CTG ACT 
Cys Arg Le" Val Met Ala Val Asp Gly Ile Asn Gln Phe Thr Ser Ile Phe Cys Leu Thr 
406 465 
GTC ATG AGC GTG GAC CGC TAC CTG GCC GTG GTA CAT CCC ACC CGC TCG GCC CGC TGG CGC 
Val Met Ser Val Asp Arg Tyr Leu Ala Val Val HIS Pro Thr Arg S; Ala Arg Trp Arg 
466 525 
ACA GCT CCG GTG GCC CGC ACG GTC AGC GCG GCT GTG RX GTG GCC TCA GCC GTG GTG GTG 
Thr Ala Pro Val Ala Arg Thr Val Ser Ala Ala Val Trp Val Ala Ser Ala Val Val Val 
526 585 
CTG CCC GTG GTG GTC TTC TCG GGA GTG CCC CGC GGC ATG AGC ACC TGC CAC ATG CAG TGG 
Leu Pro Val Val Val Phe Ser Gly Val Pro Arg Gly Met Ser Thr Cys HLS Met Gln Trp 
586 645 
CCC GAG CCG GCG GCG GCC TGG CGA GCC GGC TTC ATC ATC TAC ACG GCC GCA CTG GGC TTC 
Pro Gl" Pro Ala Ala Ala Trp Arg Ala Gly Phe Ile Ile Tyr Thr Ala Ala Le" Gly Phe 
646 705 
TTC GGG CCG CTG CTG GTC ATC TGC CTC TGC TAC CTG CTC ATC GTG GTG AAG GTG CGC TCA 
Phe Gly Pro Le" Le" Val Ile Cys Le" Cys Tyr Le" Le" Ile Val Val Lys Val Arg Ser 
706 765 
GCT GGG CGC CGG GTG TGG GCA CCC TCG TGC CAG CGG CGG CGG CGC TCC GAA CGC AGG GTC 
Ala Gly Arg Arg Val Trp Ala Pro Ser Cys Gin Arg Arg Arg Arg Ser Glu Arg Arg Val 
766 q m 825 
ACG CGC AT0 GTG GTG GCC GTG GTG GCG CTC TTC GTG CTC TGC TGG ATG CCC TTC TAC GTG 
Th Arg Met Val Val Ala Val Val Ala Leu Phe Val Leu Cys Trp Met Pro Phe Tyr Val 
&8 885 
CTC AAC ATC GTC AAC GTG GTG TGC CCA CTG CCC GAG GAG CCT GCC TTC TTT GGG CTC TAC 
Leu Am Ile Val Asn Val Val Cys Pro Leu Pro Glu Glu Pro Ala Phe Phe Gly Leu Tyr 
886 945 
TTC CTG GTG GTG GCG CTG CCC TAT GCC AAC AGC TGT GCC AAC CCC ATC CTT TAT GGC TTC 
Phe Le" Val Val Ala Leu Pro 'Fyr Ala Asn Ser Cys Ala Asn Pro Ile Le" Tyr Gly Phe 
946 1005 
CTC TCC TAC CGC *TC AAG CAG GGC TTC CGC AGG GTC CTG CTG CGG CCC TCC CGC CGT GTG 
Leu Ser Tyr Arg Phe Lys Gin Gly Phe Arg Arg Val Le" Leu Arg Pro SF Arg Arg Val 
1006 1065 
CGC AGC CAG GAG CCC ACT GTG GGG CCC CCG GAG AAG ACT GAG GAG GAG GAT GAG GAG GAG 
Arg Ser Gln Glu Pro Thr Val Gly Pro Pro Glu Lys Thr Glu Glu Glu Asp Glu Glu Glu 
1066 1125 
GAG GAT GGG GAG GAG AGC AGG GAG GGG GGC AAG GGG AAG GAG ATG AAC GGC CGG GTC AGC 
Gl" Asp Gly Glu Gl" Ser Arg Glu Gly Gly Lys Gly Lys Glu Met Asn Gly Arg Val Ser 
1126 1185 
CAD ATC ACG CAG CCT GGC ACC AGC GGG CAG GAG CGG CCG CCC AGC AGA GTG GCC AGC AAG 
Gln Ile Thr Gln Pro Gly Thr Ser Gly Gln Glu Arg Pro Pro Ser Arg Val Ala Ser Lys 
1186 1245 
GAG CAG CAG CTC CTA CCC CAA GAG GCT TCC ACT GGG GAG AAG TCC AGC ACG ATG CGC ATC 
Glu Gin Gln Leu Le" Pro Gln Glu Ala Ser Thr Gly Glu Lys Ser Ser Thr Met Arg Ile 
1246 n 
April 1993 
AGC TAC CTG TAG GGGCCTGGGGAAAGCCGAGGAAG-3' 
Ser Tyr Leu OPA 
Fig. 1. (a) Restriction map of the human somatostatin SSTR3 genomic clone. Relevant endonuclease restriction sites of the 2.1 kb NcoVHindIII 
genomic clone are indicated. Hatched areas denote the coding region of clone with the position of putative transmembrane domains underlined 
and numbered by Roman numerals. (b) Nucleotide and deduced amino acid sequence of the human SSTR3 receptor gene. Nucleotides of JCI 
genomic clone are numbered beginning with the codon for the putative initiation methionine with the deduced amino acid sequence presented below 
the nucleotide sequence. Putative N-linked glycosylation sites are indicated by closed triangles (A). Potential phosphorylation sites for protein kinase 
A (CAMP dependent) and protein kinase C are indicated by open (0) and closed (B) squares, respectively. 
281 
Volume 321, number 2,3 FEBS LETTERS April 1993 
Fig. 2. Alignment of deduced amino acid sequence of the human SSTR3 receptor, and other members of the somatostatin receptor family. Boxed 
and shaded areas denote the conserved amino acid residues between the human SSTR3 receptor and the human and rat SSTRl, SSTRZ and SSTM 
proteins. Single letter code used to denote amino acids. 
tively. As with other members of the human somato- 
statin receptor gene family, the SSTR3 appears to be 
intronless within its coding region. 
Hydrophobicity analysis of SSTR3 reveals the pres- 
ence of seven putative transmembrane domains, charac- 
teristic of members of the superfamily of receptors 
which couple to guanine nucleotide binding proteins 
[18]. As outlined in Fig. lb, SSTR3 contains consensus 
sequence for two potential N-linked glycosylation sites 
in the amino-terminus at Asn17 and Asn3’. Moreover, 
five putative phosphorylation sites for CAMP-depend- 
ent protein kinase A and protein kinase C were found 
in the second, third cytoplasmic loops and in the 3’ 
carboxyl terminus. Regions within the second and third 
cytoplasmic loop have been implicated in G-protein 
coupling [19,20], while serine and threonine residues 
within the carboxy tail may act as potential sites for 
receptor specific kinases [21]. 
transmembrane domains, with the recently cloned rat 
SSTR3 [13,14] and displays an overall amino acid ho- 
mology of - 80%. It is of interest to note, that a con- 
served Cys residue which is found within the carboxy 
tail of most members of the G-linked receptor family, 
including SSTRl, SSTR2 and SSTR4, and which is a 
site for palmitoylation [22,23] is absent from both the 
human and rat SSTR3s. Mutation of this Cys residue, 
at least for the t9 adrenergic receptor [23] has been 
shown to modify receptor G-protein interactions. 
Moreover, the rat and human SSTR3s also differ within 
the size of the third cytoplasmic loop; the rat containing 
8 additional amino acids. Both rat and human SSTR3s 
contain stretches of acidic amino acid residues within 
the COOH tail (AA 349-360), the functional signifi- 
cance of which, if any, is unknown at present. Acidic 
peptides are, however, substrates for phosphorylation 
by receptor specific kinases (see [21]). 
Based on the deduced amino acid sequence, the great- In order to ascertain the pharmacological nature of 
est degree of amino acid homology between SSTR3 and this gene product, membranes from COS-7 cells tran- 
other cloned somatostatin receptors (SSTRl, SSTR2, siently expressing JCI-pCDps clones were measured for 
SSTR4) occur within these putative transmembrane do- the presence of high affinity [lz51]LTT SST-28 binding. 
mains (Fig. 2). Within these transmembrane domains, As depicted in Fig. 3, the expressed receptor bound 
SSTR3 shares 62%, 64% and 58% homology with radioligand in a saturable manner and with high affin- 
SSTRl, SSTR2 and SSTR4, respectively. Overall se- ity. Scatchard transformation of the binding data of 
quence homology between SSTR3 and the human SSTR3 (Fig. 3 inset) revealed a single class of high 
SSTRl is 41%, 39% with the SSTR2, and 37% with the affinity binding sites, with an estimated K. of 210 f 11 
SSTR4 receptor. Moreover, as shown in Fig. 2, the pM and a receptor density (&,A of 189 + 11 fmol/mg 
human SSTR3 is 97% homologous, within putative protein (n = 3). No specific binding of radioligand was 
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Fig. 3. (a) Saturation isotherms of [1251]LTT SST-28 binding to membranes prepared from COS-7 cells transfected with SSTR3 DNA. Membranes 
prepared from COS-7 cells transfected with the human SSTR3 gene were incubated with increasing concentrations of radioligand and assayed for 
receptor binding activity in the absence or presence of 100 nM LTT SST-28 to define non-specific binding as described in section 2. Scatchard 
analysis of the binding data (shown in inset) revealed abinding capacity (B_) of 189 f 11 fmopmgprotein and an estimated affinity (&) of 210 f 11 
pM for SSTR3. Data represent mean + S.E.M. of 3 determinations each conducted in duplicate. (b) Pharmacological specificity of the cloned 
SSTR3. The concentration-dependent competitive inhibition by somatostatin analogs of [‘251]LTT SST-28 binding to the expressed SSTR3 revealed 
binding afkity for SST-14 > SST-28 in each experiment. Membranes were incubated with - 60-80 pM [‘251]L’lT SST-28 and with the indicated 
concentrations of SST-14 (0) or SST-28 (A) under equilibrium binding conditions as described in section 2 (n = 3). k; values are listed in 
Table I. 
observed in nontransfected cells (data not shown). Var- 
ious peptides (SST-14, SMS 201-995 and [o-Trp*]SST- 
14) inhibited [1251]LTT SST-28 binding in a concen- 
tration-dependent and uniphasic manner over a con- 
centration range of 10-‘“-10-7 M (Fig. 3b). The relative 
estimated dissociation [Ki] values for these ligands are 
listed in Table I and reveal a rank order of potency for 
the SSTR3 of [o-Trp*]SST-14 > SST-14 > SMS 201- 
995 > SST-28. 
Pharmacologically, some important differences be- 
tween the human and rat [13,14] SSTR3 receptors are 
evident. While the human SSTR3 receptor displays af- 
finities for the SST-14 peptide - fourfold higher than 
SST-28, the rat homolog appears to display 2- to 3-fold 
higher affinity for SST-28 than SST-14. Thus, the rank 
order of potency for the human SSTR3 is indicative of 
Table I 
Relative binding affinities of SS peptides for the cloned human SSTR3 
Peptide 
[D-Trp’]SST-14 
SST-14 
SMS 201-995 
SST-28 
K, (nM) SSTR3lSSTR4 
0.56 k 0.10 1.75 
2.09 f 0.45 1.92 
5.79 f 1.10 4.26 
7.94 f 1.26 3.61 
Inhibitory constants (x;) of various compounds for [‘251]LlT SST-28 
binding are listed in order of potency for the human SSTR3 receptor. 
Transfection of COS-7 cells with the SSTR3 receptor gene was per- 
formed as described in section 2. Dissociation constants were obtained 
using the computer program LIGAND. Ratio for estimated K, values 
for the cloned human SSTR3 and SSTR4s expressed in COS-7 cells. 
Values represent he means of three independent experiments each 
Northern blot analysis of poly(A)’ RNA from vari- 
ous primate brain regions probed with the 2.1 kb NcoIl 
Hind111 of SSTR4 revealed widely divergent distribu- 
tions. As depicted in Fig. 4, SSTR3 mRNA transcripts 
of approximately 5.0 kb in length were observed in 
monkey frontal cortex. Lower levels of mRNA expres- 
sion were observed in the cerebellum, amygdala and 
medulla. As depicted in Fig. 4 two SSTR3 mRNA tran- 
scripts were evident in these regions and may possibly 
be associated with multiple transcription or polyadenyl- 
ation sites for the SSTR3 gene [25]. Little or no SSTR3 
mRNA was detected in the monkey striatum, hip- 
pocampus, and olfactory tubercle. The brain distribu- 
tion of the SSTR3 mRNA appears distinct from that of 
SSTR4, and SSTR2s [13]. 
conducted in duplicate. PCR amplification of hybrid human-hamster so- 
a SST-14 preferring receptor (see above), while the rat 
SSTR3 displays, with respect o SST-28 and SST-14, an 
inverted order of potency (SST-28 > SST-14 >% SMS- 
201-995). At present it is difficult to ascertain whether 
sequence divergence among the rat and human SSTR3s 
may be implicated in the maintenance of these pharma- 
cological profiles. The relative affinities for various so- 
matostatinergic agents for SSTR3 are lower, however, 
than that for the human SSTR4. In any event, the size 
and sequence of the third cytoplasmic loop of SSTR3 
is similar to those of the SSTRl, SSTR2 and SSTR4 
receptors, suggesting that it might be coupled to gua- 
nine nucleotide binding proteins in a similar manner. 
Preliminary data appear to indicate that in COS-7 cells 
the human SSTR3 receptor, as does the rat SSTR3, 
inhibits forskolin stimulated adenylate cyclase activity 
~241. 
283 
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*-47kb 
, 
I 
Fig. 4. Northern blot analysis of SSTR3 mRNA in monkey brain. 
Poly(A)+ (%5 &lane) RNA samples from various monkey brain 
regions were denatured, electrophoresed, transferred to nylon mem- 
branes and hybridized with a 2.1 kb NcoUZfindIII fragment encoding 
the entire SSTR3 gene. Nylon membranes were exposed for 4 days at 
-80°C with one intensifying screen. 
matic cell lines for SSTR3 showed chromosome 22 to 
be the only chromosome to which this gene segregates 
(Fig. 5), as compared to SSTRl, SSTR2 and SSTR4, 
which were found on chromosomes 14, 17 and 20, re- 
spectively (data not shown). 
The above findings document the existence of an- 
other member of the somatostatin receptor gene family. 
The cloned human SSTR3 receptor, despite less overall 
amino acid similarity, is closely related in size, structure 
and selectivity for SST-14 peptides with other members 
of the human SSTR family. Whether or not these recep- 
tors display distinctive tissue specific patterns of expres- 
sion, differential regulation and/or coupling to subtype 
specific membrane signalling pathways remains to be 
Chromosome22 + - - - + - - + - - + - - 
Fig. 5. Chromosomal ocation of the human SSTR3 receptor gene. 
Ethidium bromide stained agarose gel of hybrid hamster-human so- 
matic cell lines (BIOS Corp.) analyzed for the presence of SSTR3 
receptor DNA using the PCR as described in section 2. Oligonucleo- 
tide primers flanking 5’ translated and untranslated sequence of the 
SSTR3 gene were used to generate an amplified product of approxi- 
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determined. The present study points to a remarkable 
degree of genetic diversity within the SS-14 receptor 
gene subclass alone, and predicts an extensive receptor 
gene family which will need to be fully characterised at 
the molecular level for understanding the biological 
functions of the somatostatin receptor systems in health 
and disease. 
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